As most of the heritability of complex traits is attributed to common and low frequency genetic variants, imputing them by combining genotyping chips and large sequenced reference panels is the most cost-effective approach to discover the genetic basis of these traits. Association summary statistics from genome-wide meta-analyses are available for hundreds of traits. Updating these to ever-increasing reference panels is very cumbersome as it requires reimputation of the genetic data, rerunning the association scan, and meta-analysing the results. A much more efficient method is to directly impute the summary statistics, termed as summary statistics imputation. Its performance relative to genotype imputation and practical utility has not yet been fully investigated. To this end, we compared the two approaches on real (genotyped and imputed) data from 120K samples from the UK Biobank and show that, while genotype imputation boasts a 2-to 5-fold lower root-mean-square error, summary statistics imputation better distinguishes true associations from null ones: We observed the largest differences in power for variants with low minor allele frequency and low imputation quality. For fixed false positive rates of 0.001, 0.01, 0.05, using summary statistics imputation yielded an increase in statistical power by 15, 10 and 3%, respectively. To test its capacity to discover novel associations, we applied summary statistics imputation to the GIANT height meta-analysis summary statistics covering HapMap variants, and identified 34 novel loci, 19 of which replicated using data in the UK Biobank. Additionally, we successfully replicated 55 out of the 111 variants published in an exome chip study. Our study demonstrates that summary statistics imputation is a very efficient and cost-effective way to identify and fine-map trait-associated loci. Moreover, the ability to impute summary statistics is important for follow-up analyses, such as Mendelian randomisation or LD-score regression.
To account for variable sample size in summary statistics of tag SNVs, we use an 49 approach to down-weight entries in the C λ and c λ matrices for which summary 50 statistics were estimated from a GWAS sample size lower than the maximum sample 51 size in that dataset [10] . 52 For more details on our summary statistics imputation method and extensions of it, 53 see our complementary paper [10] . 54 
Results

55
To assess the performance of summary statistics imputation in realistic scenarios we 56 used two different datasets. In Section "Comparison of summary statistics imputation 57 versus genotype imputation" we compare the performance of summary statistics 58 imputation to genotype imputation, using measured and imputed genotype data from 59 120 086 individuals in the UK Biobank. In Section "Summary statistics imputation of 60 the height GWAS of the GIANT consortium", we use published association summary 61 statistics from 253 288 individuals to show that summary statistics imputation can be 62 used to identify novel associations. Both analyses are centered around the genetics of 63 human height. In the following we will often refer to two GIANT (Genetic Investigation 64 of ANthropometric Traits) publications: Wood et al. [12] , an analysis of HapMap 88 We term the 6 080 SNVs correlated with a height-associated lead SNV as associated 89 SNVs. Conversely, we refer to the 31 567 SNVs that are not correlated with any 90 height-associated lead SNV as null SNVs. For both, null and associated SNV groups, 91 the largest group of analysed variants were common and well-imputed (S1 Fig) . The 92 fraction of SNVs with low quality imputation increases with lower minor allele 93 frequency (S2 Fig) . However, the number of rare variants (MAF< 1%) were too small 94 (2 411 variants, among these only 13 associated variants) to draw meaningful 95 conclusions and hence we limited our analysis to common and low-frequency variants. 96 We focused on two aspects of the imputation results. First, we compared how 97 summary statistics imputation and genotype imputation perform relative to the ground 98 truth (direct genotyping). For this we used four measures: the root mean squared error 99 (RMSE), bias, the linear regression slope, and the correlation. Second, we calculated 100 power and false positive rate for genotype imputation and summary statistics imputation 101 directly. height-associated variants. As expected, the performance drops as the imputation 107 quality and as the MAF decrease. For well-imputed common SNVs (the largest 108 subgroup with 4 782 variants), summary statistics imputation performs on average well 109 with a correlation and a slope close to 1 (cor = 0.998 and slope = 0.98), but it drops to 110 0.90 (cor = 0.961 and slope=0.90) for low imputation quality, low-frequency variants. 111 On the other hand, for genotype imputation (Fig 2, an advantage compared to genotype imputation when α is low. As we approach lower 156 imputation quality and MAF, summary statistics imputation advantage becomes more 157 and more apparent for all range of α values. In general, whenever summary statistics 158 imputation is outperforming genotype imputation, this is because lower FPR (horizontal 159 shift), and not due to increased power. This aspect is more clearly visible in S5 Fig While previous studies have examined the role of (common) HapMap variants for 166 height [12, 17] , the impact of rare coding variants could not be investigated until 167 bespoke genotyping chips (interrogating low-frequency and rare coding variants) were 168 designed to address this question in a cost-effective manner. Such an exome chip based 169 study was conducted by the GIANT consortium in 381 000 individuals and revealed 120 170 height-associated loci, of which 83 loci were rare or low-frequency [13] . These By imputing > 6M additional SNVs summary statistics using HapMap variants [12] as 178 tag SNPs we were interested in two aspects: (1) discovering new height-associated 179 candidate loci, and (2) replicating these candidate loci in the UK Biobank and the 180 GIANT exome chip look-up ( Fig 6) . We used the HapMap-based height study and the 181 UK10K reference panel as inputs for summary statistics imputation and used all 182 HapMap SNVs as tag SNVs. We imputed variants that were available in UK10K with a 183 MAF UK10K ≥ 0.1%, as well as all reported exome variants in Marouli et al. [13] . In 184 total we imputed 10 966 111 variants, of which 9 276 018 (84%) had an imputation 185 quality ≥ 0.3.
186
We subjected all 9 276 018 variants with an imputation quality ≥ 0.3 to a scan for 187 Next, we used the UK Biobank to replicate the associations with height of these 35 193 candidate variants and subsequently grouped them into replicating (20 variants) and 194 not replicating (15 variants) (at α = 0.05/35 level).
195
An overview of the 20 replicating variants is given in Table 2 . One region had 196 already been discovered in the GIANT exome chip study: rs28929474, located in gene 197 SERPINA1. Fig 7 shows this region as locus-zoom plot with summary statistics from the 198 HapMap study, summary statistics imputation, and the exome chip study. To annotate 199 these 20 novel candidate variants further, we investigated whether they are eQTLs or 200 associated with other traits. We report this in Table 3 where we list eQTLs detected by 201 GTEx [18] and Table 4 that presents a curated association-trait list by 202 Phenoscanner [19] . In the following we describe variants that replicated in UK Biobank 203 which are either eQTLs or have previously been associated with another trait. 204 We can classify the 35 candidate loci into three categories (i), (ii) and (iii) that three candidate loci (#2, #3, #21 in S1 Table) contain borderline significant HapMap 214 signals (P -value between 10 −6 and 10 −8 in [12] ).
215
We observed that variants with higher MAF have higher chance to replicate. Among 216 the 20 candidate variants that did replicate in UK Biobank, 19 were common and one a 217 low-frequency variant (rs112635299, MAF = 2.32%). Conversely, among the 15 218 candidate variants that did not replicate in the UK Biobank, 10 are rare, three are 219 low-frequency variants, and two are common.
220
Locus #1: rs112635299 (imputed P -value 4.21 × 10 −14 ), is a proxy of rs28929474 221 (LD= 0.88), has been associated with alpha-1 globulin [20] and is associated with 222
Overview of imputation and replication scheme. This illustration gives an overview how we used > 2M GIANT HapMap summary statistics (black rectangle) as tag SNVs to impute > 10M variants with MAF≥ 0.1% in UK10K. After adjusting the summary statistics for conditional analysis we applied a selection process that resulted in 35 candidate loci. To confirm these 35 loci we used summary statistics from UK Biobank (blue) as replication as well as summary statistics from the exome chip study, if available [13] (red). Loci that had not been discovered by the exome chip study, were termed novel. multiple lipid metabolites [21] . rs28929474 was identified in the GIANT exome 223 chip study to be height-associated (P = 1.39 × 10 −45 ) [13] . The P -value 224 calculated with summary statistics imputation was P = 1.06 × 10 −13 . rs28929474 225 is a low-frequency variant (MAF= 2.3%) and replicates in the UK Biobank with 226 P = 1.66 × 10 −25 .
227
Locus #2: rs76306191 is a common variant on chromosome 1, located in gene 228 DCST1. There was no reported HapMap variant nearby to condition on. However, 229 the absolute correlation to the HapMap variant with the lowest P -value (> 10 −8 ) 230 in the same region was 0.8. One of the 122 variants reported by the exome chip 231 study, rs141845046, was in this region, but had an imputed P -value > 10 −3 . 232 rs76306191 replicated in the UK Biobank with P = 1.09 × 10 −7 . rs76306191 is 233 an eQTL in artery (tibial) for gene ZBTB7B and in thyroid gland for gene DCST2. 234
Locus #5: rs12795957 is a variant on chromosome 11 and an eQTL for gene RAD9A 235 in artery (tibial).
236
Locus #6: rs503035 is a variant on chromosome 5. It is an eQTL for gene PITX1 in 237 testis tissue. rs62623707, one of the 122 reported exome variants, was in this 238 region, but had an imputed P -value > 10 −3 . This table presents 20 regions that contain at least one imputed variant that is independent from top HapMap variants nearby and that replicated in the UK Biobank (at α = 0.05/35 level). Each row represents one region (#), indicating the SNV with the lowest conditional P -value. The first seven columns provide general information for each variant, followed by the P -value and sample size from summary statistics imputation, P -value and sample size from the UK Biobank. The last column assigns each of the 35 candidate loci to one of three groups: candidate loci (i) that were reported by [13] already, (ii) that had no reported HapMap variant nearby and (iii) that had reported HapMap variants nearby. r 2 pred,adj of all variants listed was greater than or equal to 0.3. We provide a more detailed table for all 35 variants (both replicating and not replicating) in S1 Table. (*) rs28929474, exome chip study results: P = 1.39 × 10 −45 , N = 365 451.
239
(1) [I] intronic, [E] exonic, -intergenic.
(2) MAF was computed in UK10K.
Locus #15: rs78566116 is a variant on chromosome 6. rs78566116 has been 240 associated with HPV8 seropositivity in cancer [22] , rheumatoid arthritis [23] and 241 ulcerative colitis [24] .
242
Locus #20: rs58402222 is an intronic variant on chromosome 1, located in gene 243 NASP. It is an eQTL for genes CCDC163P, MAST2 and TMEM69 in cells 244 (transformed fibroblasts); and for GPBP1L1 in thyroid tissue. 245 Replication of 55/111 reported GIANT exome chip variants 246 Next, we focussed on 122 novel variants of Marouli et al. [13] . For this analysis we did 247 not apply any MAF restrictions. Of these 122 variants, 11 variants were either not 248 referenced in UK10K or on chromosome X, and were therefore not imputed, limiting the 249 number of loci and variants to 111 (S3 Table) . By grouping results below or above the 250 P -value threshold of α = 0.05/111 we could classify variants into the ones that 251 replicated and those that failed replication. This is summarised in Table 5 This table shows SNVs which are significant eQTLs in GTEx [18] . We only report SNV-gene expression associations where the summary statistics pass the significance threshold of α = 10 −6 . The first four columns represent the region number, SNV, P -value from summary statistics imputation and the P -value in the UK Biobank. The four remaining columns are information extracted from GTEx, with the tissue name, gene name, the P -value of the association between the SNV and the gene expression, and the gene type. For each region, we only include the tissue with the lowest P -value per SNV-gene associations. The full version of this table is available in S2 Table. # refers to the region number. 
This table presents summary statistics imputation results, limited to 111 variants identified as "novel" by [13] . We summarised the results according to their allele frequency and imputation quality category. For each subgroup we calculated the fraction of top exome variants that had a P -value ≤ 0.05/111 with summary statistics imputation.
Discussion
256
In this article, we focussed on the comparison between genotype and summary statistics 257 imputation. In contrast to previous work by others and us [10, 11, 25] , here we 258 systematically assessed the performance and limitations of summary statistics 259 imputation through real data applications for different SNV subgroups characterised by 260 allele frequency, imputation quality and association status (null/associated). In 261 addition, we demonstrated the usefulness of summary statistics imputation to discover 262 novel associated regions using existing association data. Note that in this paper we used 263 an improved version of the original summary statistics imputation [11] , which uses 264 reference panel size dependent shrinking of the correlation matrix and incorporates 265 variable sample size of tag SNVs.
266
Our study design has several limitations: for replication of summary statistics from 267 European individuals we use the UK Biobank, which represents only a subset of all 268 European ancestries and is genotype-imputed (instead of sequenced), but on the other 269 hand provides a reliable resource due to its sample size. Furthermore, in UK Biobank, 270 genotype imputation done for genotyped variants can only partially be compared to 271 genotype imputation for untyped variants, as genotyped variants were used for phasing 272 (therefore genotype imputation of genotyped variants is much easier and leads 273 imputation qualities close to one, S4 Fig) . Due to the small number of height-associated 274 rare variants (13) we can not draw meaningful conclusions for this group and hence 275 avoided their analysis.
276
The summary statistics imputation method itself has several limitations too. First, 277 due to the size of publicly available sequenced reference panels we can not explore the 278 performance of rare variants (MAF< 1%). Second, the imputation quality metric 279 r 2 pred,adj tends to be inaccurate in case of small reference panels. Third, the imputation 280 of summary statistics of an untyped SNV is essentially the linear combination of the 281 summary statistics of the tag SNVs (Eq. (1) ). Such a model cannot capture non-linear 282 dependence between tag-and target SNVs [9] , which is often the case for rare 283 variants [26, 27] . In contrast, genotype imputation is able to capture such non-linear Comparison of summary statistics imputation versus genotype 289 imputation 290 We compared summary statistics imputation and genotype imputation by using 291 individual-level data from the UK Biobank, where we evaluated the imputation results 292 for 6 080 SNVs that were correlated with a height-associated variant (associated SNVs) 293 and 31 567 that were not correlated to any height-associated SNVs on the same 294 chromosome (null SNVs).
295
In general, imputation using summary statistics imputation leads to a larger RMSE 296 than genotype imputation in all twelve SNV subgroups investigated (Fig 4) . Among 297 associated SNVs, summary statistics imputation performs similar to genotype imputation 298 for well-imputed SNVs, but shows a trend for underestimation of the Z-statistics and 299 lower correlation with the true effect size for medium-and badly-imputed SNVs (Fig 2) . 300 Conversely, genotype imputation has more consistent results for most of the twelve SNV 301 subgroups (Fig 2 and 3) , that is reflected in a correlation close to one between 302 Z-statistics from genotype data and genotype imputation data.
303
Underestimation for null and associated SNVs 304 Ultimately, the underestimation of imputed Z-statistics with summary statistics 305 imputation leads to a lower type I error. We calculated power and FPR for both 306 methods and observe that for a given significance threshold, summary statistics 307 imputation has a lower FPR at the cost of lower power compared to genotype 308 imputation. This effect is amplified for SNV groups with lower imputation quality 309 ( r 2 pred,adj < 1). For associated SNVs with r 2 pred,adj < 1 we expect an underestimation for 310 associated SNVs due to the fact that we are imputing summary statistics under the null 311 model, whereas for null SNVs with r 2 pred,adj < 1 we expect an underestimation due to 312 decreased variance of the summary statistics imputation estimation.
313
Ideally, for an unbiased estimation of causal and null SNVs, the imputed Z-statistics 314 (Eq. (1)) should be divided by r 2 . However, as the imputation quality r 2 pred,adj is noisily 315 estimated from small reference panels (discussed below) and it is not guaranteed that 316 the SNV we impute is causal, we risk to overestimate the summary statistics of 317 associated SNVs. This is the reason why refrain from doing so. SNVs with an accumulation of low −log10(P )-values for well-imputed SNVs and an 320 accumulation of high −log10(P )-values for badly-imputed SNVs. We think that two 321 factors are in play here. First, mostly due to polygenicity, the genomic lambda for 322 height is λ GC = 1.94, therefore we expect even seemingly null variants to show inflation. 323 Second, for null SNVs, the sample variance of the imputed Z-statistics should be 324 proportional to the average imputation quality. We calculated for each of the null SNV 325 subgroups the ratio between the sample variance for Z-statistics from summary 326 statistics imputation and the sample variance for Z-statistics from genotype data. For 327 common null SNVs we observe a ratio that gradually decreases with imputation quality 328 (0.89 for perfectly-, 0.79 for medium-and 0.68 for badly imputed SNVs). For 329 low-frequency null variants the ratio is approximately 0.1 lower (0.82 for perfectly-, 0.70 330 for medium-and 0.52 for badly imputed SNVs). The inflation for well-imputed SNVs 331 can be explained by the genomic lambda, while for badly-imputed SNVs it is aggravated 332 by the underestimated standard error. Because the number of associated SNVs with MAF < 1% was too low (13 variants) to 336 draw any meaningful conclusions, we refrained from analysing this MAF group. One 337 other reason to exclude rare variants from this analysis is, that the reference panel used 338 (UK10K) contains 3 871 individuals and therefore estimations for LD of rare variants 339 are unreliable and rare variants can (in theory) only be covered down to MAF 340 = 1/(2 · 3 871). We believe improving summary statistics imputation for rare variants 341 will require not only larger reference panels to allow estimation of LD of rare variants, 342 but also methods which would allow non-linear tagging of variants. It should be kept in 343 mind that, just like for genotype imputation, even with very large reference panels, one 344 will not be able to impute variants with extremely rare allele counts. To investigate 345 these SNVs full genome sequencing is indispensable [28] . 346 Imputation quality 347 We find that our imputation quality measure r 2 pred,adj is conservative and probably As a showcase of the utility of summary statistics imputation we imputed Wood et 367 al. [12] to higher genomic resolution (limited to variants with MAF ≥ 0.1% as well as 368 111 previously reported exome variants) [13] , then selected imputed variants that act 369 independently from those reported in Wood et al. and replicated these with 370 independent data.
371
While Wood et al. [12] is the largest height study to date in terms of number of 372 markers (covering HapMap variants in 253 288 individuals), Marouli et al. [13] exceeds 373 their sample size by more than 100 000 individuals, but is limited to 241 419 exome 374 variants. The similarity between both GIANT studies made the exome chip study ideal 375 for replication. We chose the UK Biobank as a second replication dataset, despite its 376 limitation to individuals of British ancestry, as it covers more variants than the exome 377 chip study.
378
The ultimate goal was to find new height-associated variants. To do so, we scanned 379 through the imputed results and marked regions that had at least one variant 380 confidently imputed ( r 2 pred,adj ≥ 0.3) with an association with P ≤ 10 −8 and that acted 381 Biobank have borderline significant HapMap signals in close proximity (P -value 386 between 10 −6 and 10 −8 in [12] ) and were therefore not reported in the study in 2014.
387
The 15 non-replicating candidate loci were on average on a lower allele frequency 388 spectrum (ten are rare, three are low-frequency variants, and two are common). Allele 389 frequency was higher among the 20 replicating candidate variants (19 were common and 390 one a low-frequency variant).
391
Replicating GIANT exome chip imputation results 392 We then focussed on the summary statistics imputation of the the 111 reported exome 393 chip variants [13] . Knowing from our previous findings that rare variants are challenging 394 to impute due to reference panel size, we expected to retrieve a larger fraction of 395 common and low-frequency than rare variants. S8 Fig shows that we retrieved 49.5%
396
(55) of the variants when using a strict Bonferroni corrected threshold (at α = 0.05/111 397 level, Table 5 ). More specifically, of the 111 top variants (78 common, 25 low-frequency, 398 eight variants rare) 83 variants were imputed with high confidence ( r 2 pred,adj ≥ 0.7). Of 399 these, 53 were retrieved when using the typical candidate SNV threshold (0.05/111).
400
Among variants with lower imputation quality only two common and medium-imputed 401 variants could be retrieved. As shown in Fig 2 and 5 , the power of summary statistics 402 imputation decreases with lower MAF and imputation quality. In summary, we have evaluated the performance of our recently improved summary 405 statistics imputation method in terms of different measures and shown that summary 406 statistics imputation is a very efficient and fast method to separate null from associated 407 SNVs. However, genotype imputation outperforms summary statistics imputation by a 408 clear margin in terms of accuracy of effect size estimation. By imputing GIANT
409
HapMap-based summary statistics we have demonstrated that summary statistics 410 imputation is a rapid and cost-effective way to discover novel trait associated loci. We 411 also highlight that the principal limitations of summary statistics imputation are rooted 412 in the LD estimation and in imputing very rare variants with sufficient confidence. analysis we used Caucasians individuals (amongst people who self-identified as British) 420 from the first release of the genetic data (n = 120 086). For SNVs, the number of 421 individuals range between n = 3 431 and n = 120 082. Additionally to custom SNP 422 array data, UK Biobank contains imputed genotypes [30] . A subset of 820 967 variants 423 were genotyped and imputed, and 72M variants were imputed by UK Biobank, using 424 SHAPEIT2 and IMPUTE2 [30] . 425 
Imputation of height GWAS summary statistics conducted in UK Biobank 426
We imputed GWAS Z-statistics (ran on directly genotyped data) within 1 Mb-wide 427 regions, by blinding one at the time and therefore allowing the remaining SNVs to be 428 used for tagging. As tag SNVs we used all SNVs except the focal SNV within a 1.5 Mb 429 window.
430
Selection of regions and SNVs
431
We selected 706 regions in total, consisting of 535 loci containing height-associated 432 SNVs [12, 13] and 171 regions not containing any height-associated (all P ≥ 10 −5 ) SNV. 433 More specifically, within each height-associated region we only imputed SNVs that have 434 LD max > 0.2. LD max was defined as the largest squared correlation between a SNV and 435 all height-associated SNVs on the same chromosome. In the 171 null regions we chose 436 only those variants with LD max ≤ 0.05 with any associated marker on the same 437 chromosome. These selection criteria lead to 44 992 variants being imputed. We did not 438 analyse palindromic SNVs (A/T and C/G) (3 306 variants), SNVs with missing 439 genotypes for more than 36 024 (30%) individuals (2 317 variants), SNVs with MAF 440 < 1% (3 010 variants). These restrictions left us with 37 467 of the 44 992 imputed 441 SNVs.
442
Comparison of summary statistics imputation and genotype imputation 443 To compare the performance between summary statistics imputation and genotype 444 imputation followed by association we compared each method to the directly genotyped 445 data association as gold standard. We used RMSE, bias, correlation, and the regression 446 slope (no intercept) to evaluate these approaches against the truth.
447
More precisely, the RMSE and the Bias for a set of k = 1 . . . K SNVs is:
being the Z-statistic resulting from summary statistics imputation for SNV 448 k and Z k the Z-statistic resulting from genotype data for SNV k (our gold standard).
449
Likewise, we replaced Z SSimp k with Z GT imp k , to calculate RMSE and bias for genotype 450 imputation.
451
For genotype summary statistics from associated SNVs that resulted from data with 452 partial sample size, we computed an upsampled Z-statistics, where Z u represents the 453 Z-statistics for SNV u, N u the sample size of SNV u and N max the maximal sample size 454 within the study: Z * u = Z u · Nmax Nu . Whenever we use Z-statistics from associated 455 genotype data we use this upsampled version Z * .
456
Additionally, we calculated power and false positive rate (FPR) for each method.
457
For SNVs with a real association we calculated the power as the fraction of SNVs with a 458 P ≤ α, whereas for SNVs with no association we calculated FPR as the fraction of 459 SNVs with P ≤ α. We varied α between 0 and 1 and visualised FPR versus power for 460 each method.
461
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Stratifying results
462
The obtained (summary statistics) imputation results were grouped based on the HapMap SNVs [12] , leading to the discovery of 423 height-associated loci (697 variants). 476 Later, Marouli et al. [13] published summary statistics of the exome array meta-analysis 477 (241 419 SNVs in up to 381 625 individuals), finding 122 novel variants (located in 120 478 loci) associated with height. Of the 122 exome variants, four were not available in 479 UK10K and seven were on chromosome X, and could therefore not be imputed 480 (because [12] did not include chromosome X), leaving 111 variants. We refer to the 481 summary statistics by Wood et al. [12] as HapMap study, and to Marouli et al. [13] as 482 exome chip study.
483
Summary statistics imputation of Wood et al. 484 We imputed all non-HapMap variants that were available in UK10K, using the summary 485 statistics in [12] as tag SNVs. In general, we only imputed variants with 486 MAF UK10K ≥ 0.1% (this allows a minimal allele count of 8 0.001 · 3781 · 2), except for 487 the 111 exome variants reported in [13] , which we imputed regardless of their MAF. We 488 divided the genome into 2 789 core windows of 1 Mb. We imputed the summary 489 statistics of each variant using the tag SNVs within its respective window and 250 Kb 490 on each side. Fig 6 gives an overview of the datasets and methods involved.
491
Definition of a candidate locus 492
After applying summary statistics imputation we screened for SNVs with r 2 pred,adj ≥ 0.3 493 and an (imputed) P -value ≤ 10 −8 and applied conditional analysis, aiming to limit the 494 results to SNVs acting independently from known HapMap findings. The significance 495 threshold of 10 −8 was chosen based on the effective number of SNVs evaluated 496 (< 9 276 018). For each imputed 1 Mb window, we started the conditional analysis by 497 defining two sets of SNVs. The first set contained all imputed SNVs that had an 498 imputed P -value ≤ 10 −8 , ranging from position bp (1) to bp (2) . The second SNV set 499 contained all reported HapMap SNVs (697 in total) within a range of bp (1) − 1 Mb and 500 bp (2) + 1 Mb. Having two SNV sets -the first set with newly detected variants, the 501 second set with reported HapMap variants -we could then condition each SNV in the 502 first set on all SNVs in the second set, using approximate conditional analysis [32] We replicate our findings using our UK Biobank height GWAS results and for SNVs 510 present on the exome chip we also use the recent height GWAS [13] . For both attempts 511 to replicate our findings, UK Biobank and the exome chip study, the significance 512 threshold for replication is α = 0.05/k, with k as the number of candidate loci.
513
For replication using UK Biobank we used summary statistics based on the latest 514 release of genetic data with n = 336 474 individuals, provided by the Neale lab [33] . For 515 SNVs that were not present in the latest release we used summary statistics from the 516 first release of genetic data (n = 120 086)).
517
Annotation of candidate loci 518 We use two databases to annotate newly discovered SNVs. First, we use GTEx [18] , an 519 eQTL database with SNV-gene expression association summary statistics for 53 tissues. 520 Second, we conduct a search in Phenoscanner [19] , to identify previous studies (GWAS 521 and metabolites) where the newly discovered SNVs had already appeared. For these 522 two databases we report the respective summary statistics that pass the significance 523 threshold of α = 10 −6 . We only extract the information for variants that were defined 524 as as novel discoveries.
525
Reference panels 526 To estimate LD structure in C and c (Eq. (1)) we used 3 781 individuals from UK10K 527 data [34, 35] summary statistics imputation (y-axis). To avoid clumping of dots, we used tiles varying 561 from grey (few dots) to black (many dots). The identity line is dotted. Z-statistics of SNP-array study on the y-axis. Each dot shows one of the 2 601 variants 573 that had LD max > 0.1 (LD with one of the top variants in the exome [13] or HapMap 574 study [12] ). To make the density more visible, dots have been made transparent. The In the bottom window we mark dots as black if it is are 590 part of the 122 reported hits of [13] . In the top window we mark the rs-id of variants 591 that are part of the 122 reported variants of [13] in bold black, and if they are part of 592 the 697 variants of [12] in bold orange font. Variants that are black (plain) are imputed 593 variants (that had the lowest conditional P -value). Variants in orange (plain) are Replication of exome variant rs28929474 is a missense variant on chromosome 14 in gene SERPINA1, low-frequency (MAF=2.3%), imputed summary statistics (P SSimp = 1.06× −13 ), replication in the UK Biobank (P UKBB = 6.49× −78 ). rs112635299 has the strongest signal in this region (P = 4.21 × 10 −14 ), but is highly correlated to rs28929474 (LD=0.95). This figure shows three datasets: Results from the HapMap and the exome chip study, and imputed summary statistics. The top window shows HapMap P -values as orange circles and the imputed P -values (using summary statistics imputation) as solid circles, with the colour representing the imputation quality (only r 2 pred,adj ≥ 0.3 shown). The bottom window shows exome chip study results as solid, grey dots. Each dot represents the summary statistics of one variant. The x-axis shows the position (in Mb) on a ≥ 2 Mb range and the y-axis the −log10(P )-value. The horizontal line shows the P -value threshold of 10 −6 (dotted) and 10 −8 (dashed). Top and bottom window have annotated summary statistics: In the bottom window we mark dots as black if it is are part of the 122 reported hits of [13] . In the top window we mark the rs-id of variants that are part of the 122 reported variants of [13] in bold black, and if they are part of the 697 variants of [12] in bold orange font. Variants that are black (plain) are imputed variants (that had the lowest conditional P -value). Variants in orange (plain) are HapMap variants, but were not among the 697 reported hits. Each of the annotated variants is marked for clarity with a bold circle in the respective colour. The genes annotated in the middle window are printed in grey if the gene has a length < 5 000 bp or is an unrecognised gene (RP-).
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